CIPLA | AUROBINDO PHARMA | CIPLA/ AUROBINDO PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 32.8 | 12.3 | 265.7% | View Chart |
P/BV | x | 4.0 | 1.3 | 299.4% | View Chart |
Dividend Yield | % | 0.5 | 1.6 | 30.2% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-22 |
AUROBINDO PHARMA Mar-22 |
CIPLA/ AUROBINDO PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,083 | 1,064 | 101.8% | |
Low | Rs | 806 | 584 | 138.0% | |
Sales per share (Unadj.) | Rs | 269.7 | 400.3 | 67.4% | |
Earnings per share (Unadj.) | Rs | 31.7 | 45.7 | 69.4% | |
Cash flow per share (Unadj.) | Rs | 44.8 | 64.9 | 68.9% | |
Dividends per share (Unadj.) | Rs | 5.00 | 9.00 | 55.6% | |
Avg Dividend yield | % | 0.5 | 1.1 | 48.5% | |
Book value per share (Unadj.) | Rs | 257.8 | 419.4 | 61.5% | |
Shares outstanding (eoy) | m | 806.81 | 585.94 | 137.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 2.1 | 170.1% | |
Avg P/E ratio | x | 29.8 | 18.0 | 165.2% | |
P/CF ratio (eoy) | x | 21.1 | 12.7 | 166.3% | |
Price / Book Value ratio | x | 3.7 | 2.0 | 186.5% | |
Dividend payout | % | 15.8 | 19.7 | 80.1% | |
Avg Mkt Cap | Rs m | 762,177 | 482,799 | 157.9% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 35,299 | 34,509 | 102.3% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 217,633 | 234,555 | 92.8% | |
Other income | Rs m | 3,217 | 3,226 | 99.7% | |
Total revenues | Rs m | 220,851 | 237,781 | 92.9% | |
Gross profit | Rs m | 43,298 | 42,566 | 101.7% | |
Depreciation | Rs m | 10,520 | 11,265 | 93.4% | |
Interest | Rs m | 1,064 | 486 | 218.6% | |
Profit before tax | Rs m | 34,933 | 34,040 | 102.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 9,338 | 7,256 | 128.7% | |
Profit after tax | Rs m | 25,595 | 26,784 | 95.6% | |
Gross profit margin | % | 19.9 | 18.1 | 109.6% | |
Effective tax rate | % | 26.7 | 21.3 | 125.4% | |
Net profit margin | % | 11.8 | 11.4 | 103.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 147,108 | 181,227 | 81.2% | |
Current liabilities | Rs m | 49,129 | 81,560 | 60.2% | |
Net working cap to sales | % | 45.0 | 42.5 | 106.0% | |
Current ratio | x | 3.0 | 2.2 | 134.8% | |
Inventory Days | Days | 63 | 25 | 250.9% | |
Debtors Days | Days | 6 | 62 | 9.2% | |
Net fixed assets | Rs m | 119,415 | 155,104 | 77.0% | |
Share capital | Rs m | 1,614 | 586 | 275.4% | |
"Free" reserves | Rs m | 206,364 | 245,174 | 84.2% | |
Net worth | Rs m | 207,977 | 245,760 | 84.6% | |
Long term debt | Rs m | 4,162 | 2,492 | 167.0% | |
Total assets | Rs m | 266,523 | 336,331 | 79.2% | |
Interest coverage | x | 33.8 | 71.0 | 47.7% | |
Debt to equity ratio | x | 0 | 0 | 197.4% | |
Sales to assets ratio | x | 0.8 | 0.7 | 117.1% | |
Return on assets | % | 10.0 | 8.1 | 123.4% | |
Return on equity | % | 12.3 | 10.9 | 112.9% | |
Return on capital | % | 17.0 | 13.9 | 122.0% | |
Exports to sales | % | 26.2 | 31.1 | 84.5% | |
Imports to sales | % | 8.2 | 11.9 | 68.6% | |
Exports (fob) | Rs m | 57,094 | 72,862 | 78.4% | |
Imports (cif) | Rs m | 17,803 | 27,965 | 63.7% | |
Fx inflow | Rs m | 60,180 | 77,245 | 77.9% | |
Fx outflow | Rs m | 17,803 | 31,524 | 56.5% | |
Net fx | Rs m | 42,376 | 45,721 | 92.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 33,259 | 50,165 | 66.3% | |
From Investments | Rs m | -18,719 | -32,116 | 58.3% | |
From Financial Activity | Rs m | -15,998 | -29,693 | 53.9% | |
Net Cashflow | Rs m | -1,323 | -11,674 | 11.3% |
Indian Promoters | % | 13.5 | 48.8 | 27.7% | |
Foreign collaborators | % | 20.1 | 3.1 | 655.7% | |
Indian inst/Mut Fund | % | 49.0 | 38.0 | 128.9% | |
FIIs | % | 27.6 | 20.7 | 133.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 66.4 | 48.2 | 137.8% | |
Shareholders | 418,910 | 359,684 | 116.5% | ||
Pledged promoter(s) holding | % | 0.0 | 15.9 | - |
Compare CIPLA With: DR. REDDYS LAB SUN PHARMA LUPIN PIRAMAL ENTERPRISES ZYDUS LIFESCIENCES
Indian share markets traded in a rangebound manner throughout the day to end on a flat note.